- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01507298
Physical Activity and Gastrointestinal Investigations
An Observational Study to Compare the Outcomes of Ambulatory Gastrointestinal Investigations With Physical Activity Using Accelerometry.
This is an observational study, which aims to compare the outcomes of ambulatory gastrointestinal investigations with physical activity using accelerometry. An ambulatory study refers to one in which the patient is monitored freely, often outside of the hospital environment. For this the investigators will use a lightweight (7.4g) tri-axial accelerometer worn behind the ear.
Hypothesis 1 There is no change in the amount or nature of physical activity taken by patients during ambulatory oesophageal pH monitoring or capsule endoscopy.
Hypothesis 2 There is no correlation between physical activity levels and speed of gastrointestinal transit.
Study Overview
Status
Conditions
Detailed Description
For capsule endoscopy, the investigators are interested in how physical activity affects the speed of capsule transit through the GI tract. Capsule endoscopy involves a patient swallowing a pill which contains a camera, in order to image the parts of the bowel that a conventional endoscope cannot reach. A rapid transit may result in insufficient mucosal visualisation, which would reduce the sensitivity of the investigation.
For oesophageal pH monitoring, it is essential that the patient behaves as they would normally to produce measurements that represent a standard day. Using accelerometry, the investigators can compare the amount, and nature, of physical activity taken throughout the investigation to that of the preceding day, or week. In addition, further analysis of motion data captured will allow us to correlate specific activities and body orientation with pH readings to get a better insight into the pathophysiology of a patient's condition.
The studies will be conducted over 6-9 months in Imperial College Trust's medical outpatient service. All patients undergoing capsule endoscopy or ambulatory oesophageal monitoring will be asked to consider participating. Patients will receive the eAR sensor up to 2 days before their investigation, and will be asked to wear it until the end of their investigation (not whilst sleeping). Capsule endoscopy normally takes less than 12 hours, and pH monitoring takes between 24 and 48 hours. Participation makes no difference to the standard or type of care that they will receive, the sensor data is additional.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W2 1NY
- Imperial College Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Planned 24 hour oesophageal pH monitoring study, or capsule endoscopy
Exclusion Criteria:
- Undergone previous capsule endoscopy or ambulatory oesophageal pH test
- Currently a hospital in-patient
- Severe mobility disorder (unable to walk or mobilise independently)
- Age less than 18 or above 65
- Physically unable to wear eAR sensor (eg. bilateral hearing aids or particularly small ears)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Capsule endoscopy
|
24 hour oesophageal pH study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical Activity Change (%)
Time Frame: Difference between baseline (2 days average) and test day (during pH monitoring)
|
The primary outcome measure is amount of physical activity undertaken by participants throughout the study period. Participant motion data will be collected using a tri-axial accelerometer in the eAR sensor. Signal processing methods will be used to produce an activity index in the form of a numerical value, from the raw data. Activity levels were grouped at 1- minute intervals into restful, low, moderate or high intensity activity. Activity levels were calibrated for each participant, classifying activity into quartiles, where the most inactivity was labelled 'Restful', 2nd quartile 'low intensity', 3rd quartile 'moderate intensity' and upper quartile 'high intensity'. This provided a personalised activity profile with which to compare activity during the investigation. |
Difference between baseline (2 days average) and test day (during pH monitoring)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Relative Intensity of Daily Activities (%)
Time Frame: Difference between baseline (2 days average) and test day (during pH monitoring)
|
Measuring the changes in restful (activity equivalent to sitting), low (activity equivalent to a slow walk), moderate (activity equivalent to a brisk walk) and high intensity activity (activity equivalent to running). Including subject-specific activity intensity quartiles, were calculated and compared. |
Difference between baseline (2 days average) and test day (during pH monitoring)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard M Kwasnicki, BSc Hons, Imperial College London
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRO1766
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastro-oesophageal Reflux Disease
-
NorgineCompletedAcid Reflux | Gastro Oesophageal Reflux DiseaseUnited Kingdom
-
Grubnik VolodymyrCompletedGastro Oesophageal Reflux Disease
-
Institute of Child HealthCompletedGastro-Oesophageal RefluxUnited Kingdom
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedEsophagitis | Gastro Oesophageal Reflux DiseaseIreland
-
Studio Osteopatico Busto ArsizioRecruitingGastro-oesophageal Reflux DiseaseItaly
-
SOFAR S.p.A.CompletedGastro-oesophageal Reflux DiseaseItaly
-
Janssen-Cilag International NVCompletedGastroesophageal Reflux Disease | GERD | Gastro-oesophageal Reflux | Gastro-Esophageal Reflux | Esophageal Reflux
-
Manchester University NHS Foundation TrustCompletedGastro-oesophageal RefluxUnited Kingdom
-
Showa Inan General HospitalWithdrawnGastro-oesophageal RefluxJapan